Search

Displaying results 1881 - 1890 of 9132 in total
  1. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    body weight of at least 40 kg. … Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate.[L51374] It binds to a different epitope compared [tralokinumab].

  2. Drug

    Gallium Ga-68 gozetotide

    go.drugbank.com/drugs/DB16019
    ApprovedInvestigational

    [A225396] In nearly all prostate cancers, malignant cells express a transmembrane protein called prostate-specific membrane antigen (PSMA). … Gallium (Ga) 68 prostate-specific membrane antigen (PSMA)-11, or Ga-68 gozetotide, is a radiopharmaceutical agent used to identify and assess prostate-specific membrane antigen (PSMA)-positive lesions

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Halcinonide

    go.drugbank.com/drugs/DB06786
    ApprovedWithdrawn

    Halcinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and is distributed as a cream and ointment.

  4. Drug

    Oftasceine

    go.drugbank.com/drugs/DB11184
    Approved

    Oftasceine is also referred to as Fluorexon. It is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent.

  5. Drug

    Nalmefene

    go.drugbank.com/drugs/DB06230
    ApprovedInvestigationalWithdrawn

    [L40684] It acts as an antagonist at the mu (μ)-opioid and delta (δ)-opioid receptors and a partial agonist at the kappa (κ)-opioid receptor. … Nalmefene, a 6-methylene analogue of [naltrexone], is an opioid receptor antagonist.

  6. Drug

    Abemaciclib

    go.drugbank.com/drugs/DB12001
    ApprovedInvestigational

    Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity

    Categories: MATE 1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  7. Drug

    Kappadione

    go.drugbank.com/drugs/DB09332
    Approved

    It has been found to have carcinogenic potential in mammalian cells as well as cytotoxic properties [L1544]. … Studies involving the active metabolite of this formulation, menadione, showed oocyte toxicity in a study of mice [L1544].

  8. Drug

    Velpatasvir

    go.drugbank.com/drugs/DB11613
    ApprovedInvestigational

    Velpatasvir acts as a defective substrate for NS5A (Non-Structural Protein 5A), a non-enzymatic viral protein that plays a key role in Hepatitis C Virus replication, assembly, and modulation of host immune … Since June 2016, Velpatasvir has been available as a fixed dose combination product with [DB08934], as the commercially available product Epclusa.

  9. Drug

    Dordaviprone

    go.drugbank.com/drugs/DB14844
    ApprovedInvestigational

    [L53833] Dordaviprone was initially studied as an anticancer agent that induces TNF-Related Apoptosis-Inducing Ligand (TRAIL). … [L53838] It is used to treat patients with diffuse midline glioma harboring an H3 K27M mutation.

    Synonyms: 7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo(1,2-A)pyrido(3,4-E)pyrimidin-5(4H)-one, 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimidin-5(1H)-one
  10. Drug

    Maribavir

    go.drugbank.com/drugs/DB06234
    ApprovedInvestigational

    Maribavir is an inhibitor of the cytomegalovirus (CMV; HHV5) pUL97 kinase which is used to treat CMV infections in patients post-transplantation. … [A242557] Maribavir is novel in that it instead targets the CMV pUL97 kinase, thereby providing an effective alternative treatment option in cases of resistant infections.